Answers are grounded in this paper and cite their sources.
Investigates the impact of pulmonary metastases on survival in patients with metastatic hormone-sensitive prostate cancer, suggesting new treatment considerations.
BACKGROUND/AIM: Among visceral metastases, while the extremely poor prognosis of liver metastases is widely recognized, clinical significance of lung metastases (LM) remains poorly understood. This study investigated the clinical profiles and prognostic impact of LM in metastatic hormone-sensitive prostate cancer (mHSPC). PATIENTS AND METHODS: We reviewed the clinical records of 1445 patients from multiple institutions who had mHSPC with bone and/or lung metastases between 1999 and 2025. Castration-resistant prostate cancer progression-free survival (CRPC-PFS) and overall survival (OS) were examined. Multivariate Cox proportional hazard modeling and Kaplan-Meier curves were employed to study prognostic significance. Irrespective of the volume of bone metastases, no significant difference was observed in the incidence of LM. CONCLUSION: mHSPC patients with LM exhibited a distinct clinical profile and more favorable prognosis in high-volume disease population. Tumor volume classification based on the presence of LM may require reevaluation to better guide treatment selection for patients with mHSPC.
No takes yet. Share an insight, caveat, or question.
YAMADA et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: